Global Pharma Healthcare Private Limited

Global Pharma Healthcare Private Limited, established in 1986, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U51102TN1986PTC013099. As of March 2022, Global Pharma reported a paid-up capital of ₹11.60 crore, with an authorized capital of ₹12.50 crore. The company's registered office is located at Third Floor, 2A Ganga Nagar, Fourth Street, Kodambakkam, Chennai, Tamil Nadu, 600024, India.

Global Pharma specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a significant presence in over 40 countries, with more than 700 product registrations. Their manufacturing facility in Chennai spans over 75,000 square feet and is certified by EU-GMP and WHO-GMP standards, ensuring high-quality production processes.

Global Pharma's primary manufacturing facility is situated in Chennai, Tamil Nadu, India. The plant covers over 75,000 square feet and is designed for large-scale, precision-controlled pharmaceutical production. It is certified by EU-GMP and WHO-GMP standards, reflecting the company's commitment to maintaining high-quality manufacturing processes. The facility is powered entirely by solar energy, demonstrating the company's dedication to sustainable manufacturing practices.

The leadership team at Global Pharma Healthcare Private Limited comprises:

• Juma Venkatesh: Managing Director since July 26, 2006.

• Manickam Kamalakannan: Director since April 6, 2012.

• Balakrishnan Rajendran: Director since December 15, 2011.

These leaders bring extensive experience and expertise to the company's strategic direction and operations.

Global Pharma Healthcare Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Chennai holds EU-GMP and WHO-GMP certifications, facilitating market access in these regions. Additionally, Global Pharma has received approvals from over 20 Ministries of Health worldwide, indicating a broad acceptance of its products in various international markets.

Global Pharma Healthcare Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's extensive product registrations and regulatory approvals from the European Union (EU-GMP) and the World Health Organization (WHO-GMP) have facilitated its entry into these regions. This strategic expansion underscores Global Pharma's commitment to improving access to affordable medications in diverse global markets.

Global Pharma Healthcare Private Limited demonstrates a diversified geographic strategy by exporting to over 40 countries across Asia, Africa, Latin America, the Commonwealth of Independent States (CIS), and the Middle East. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The company's commitment to quality, as evidenced by its EU-GMP and WHO-GMP certifications, supports its strategic direction of expanding into new markets while maintaining high standards.

Global Pharma Healthcare Private Limited's manufacturing facility in Chennai is registered with the U.S. Food and Drug Administration (FDA). However, in October 2023, the FDA issued a warning letter to the company regarding deficiencies in its manufacturing practices, including inadequate testing of incoming materials and failure to ensure the suitability of active pharmaceutical ingredients and packaging materials. This indicates that while the company has access to the U.S. market, it must address these compliance issues to maintain its standing.

Global Pharma Healthcare Private Limited's manufacturing facility in Chennai holds certifications from both the World Health Organization (WHO-GMP) and the European Union (EU-GMP). These certifications affirm the company's adherence to international quality standards in pharmaceutical manufacturing. Such certifications are crucial for market access in various regions and reflect the company's commitment to maintaining high-quality production processes.

Global Pharma Healthcare Private Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Chennai is certified by WHO-GMP and EU-GMP standards, which are recognized by the CDSCO. This compliance ensures that the company's products meet the regulatory requirements for both domestic and international markets.

In October 2023, the U.S. Food and Drug Administration (FDA) issued a warning letter to Global Pharma Healthcare Private Limited concerning deficiencies in its manufacturing practices. The FDA cited inadequate testing of incoming materials and failure to ensure the suitability of active pharmaceutical ingredients and packaging materials. Addressing these issues is essential for the company to maintain its market access and uphold its reputation for quality.

Global Pharma Healthcare Private Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international manufacturers. While specific market share data is not available, the company's extensive product portfolio and international certifications position it as a significant player in the market. The company's focus on quality, as evidenced by its EU-GMP and WHO-GMP certifications, and its commitment to sustainability, with a 100% solar-powered manufacturing facility, provide competitive advantages in the industry.

Global Pharma Healthcare Private Limited's key differentiators include its extensive product portfolio, with over 700 product registrations across more than 40 countries, and its commitment to quality, demonstrated by EU-GMP and WHO-GMP certifications. Additionally, the company's manufacturing facility is powered entirely by solar energy, reflecting its dedication to sustainable practices.

Global Pharma Healthcare Private Limited's strategic direction focuses on expanding its global footprint by entering new markets and enhancing its product offerings. The company's adherence to international quality standards, such as EU-GMP and WHO-GMP certifications, supports its strategy of maintaining high-quality manufacturing processes. Addressing the FDA's concerns from the October 2023 warning letter is crucial for the company's future outlook and its ability to sustain and grow its market presence.

Global Pharma Healthcare Private Limited's supplier assessment practices have been called into question by the FDA, which cited inadequate testing of incoming materials and failure to ensure the suitability of active pharmaceutical ingredients and packaging materials. Addressing these issues is essential for the company to maintain its reputation for quality and reliability in the pharmaceutical industry.

Importers should verify the following certifications when considering products from Global Pharma Healthcare Private Limited:

• EU-GMP Certification: Confirms compliance with European Good Manufacturing Practices.

• WHO-GMP Certification: Indicates adherence to World Health Organization Good Manufacturing Practices.

• ISO Certifications: Demonstrate compliance with international quality management standards.

These certifications can typically be verified through the company's official website or by contacting the relevant regulatory bodies.

When conducting due diligence on Global Pharma Healthcare Private Limited, consider the following steps:

• Review Regulatory Compliance: Ensure the company holds valid EU-GMP, WHO-GMP, and ISO certifications.

• Assess Manufacturing Practices: Verify that the company has addressed the FDA's concerns from the October 2023 warning letter regarding material testing and supplier qualifications.

• Evaluate Financial Health: Examine the company's financial statements for profitability and growth trends.

• Inspect Product Quality: Request samples and conduct quality assessments to ensure product standards meet expectations.